IMF Chairman Dr. Brian G.M. Durie discusses some important new findings from the 2021 American Society of Clinical Oncology (ASCO) annual meeting that took place virtually from June 4-8 this year, and from the subsequent European Hematology Association’s (EHA) annual meeting.
He highlights scientific abstracts from these meetings that discuss the following topics:
- Immune therapies, including CAR T-cell therapies and bispecifics
- Four-drug combinations, including those that add daratumumab to current three-drug regimens
- Treatment of high-risk disease
- The benefits of whole-body MRI versus PET/CT scans in baseline imaging studies
- The emerging role of mass spectrometry for low-level disease monitoring
Dr. Durie explains this data in approachable terms that patients and caregivers can use in their everyday care decision-making.
_______________
Improving Lives | Finding the Cure
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF! bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard KZfaq License
In most cases, captions are autogenerated by KZfaq.